A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX 23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX 23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2018

At a glance

  • Drugs V 114 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal vaccine
  • Indications Pneumococcal infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Acronyms PNEU-WAY
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 12 Jul 2018 Status changed from not yet recruiting to recruiting.
    • 12 Jul 2018 According to a Pfenex media release, company has received milestone payment from Merck associated with the initiation of this trial.
    • 05 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top